Infinity Holdings confirms no encumbrance of shares in Jagsonpal Pharmaceuticals for FY26

1 min read     Updated on 04 Jun 2026, 03:00 AM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Infinity Holdings disclosed that it did not encumber any shares in Jagsonpal Pharmaceuticals Limited during FY26, as per SEBI Regulation 31(4). The declaration, dated April 06, 2026, confirms no direct or indirect pledging of shares by the promoter or persons acting in concert.

powered bylight_fuzz_icon
42067800

*this image is generated using AI for illustrative purposes only.

Infinity Holdings has confirmed that it did not create any encumbrance on its shares in Jagsonpal Pharmaceuticals Limited during the financial year ended March 31, 2026. The declaration, submitted on April 06, 2026, was made in accordance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires promoters to disclose any pledging or encumbrance of shares to ensure transparency for shareholders.

The disclosure covers both direct and indirect encumbrances. Infinity Holdings stated that no such activity was undertaken by it or by persons acting in concert with it throughout FY26. The filing was addressed to the Board of Directors and the Company Secretary of Jagsonpal Pharmaceuticals Limited , with copies sent to the Audit Committee and related entities such as Infinity Capital and Infinity Portfolio Holdings.

Regulatory Context

The filing is a mandatory compliance requirement under SEBI takeover regulations. It serves to inform the stock exchanges and the company's shareholders about the status of the promoter's holdings. A nil encumbrance status indicates that the promoter's shares are free from pledges, which is generally viewed as a positive indicator of corporate governance and financial stability.

Key Details of the Disclosure

Detail Information
Disclosing Entity Infinity Holdings
Target Company Jagsonpal Pharmaceuticals Limited
Regulation SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Regulation 31(4)
Period Covered Financial year ended March 31, 2026
Encumbrance Status None
Filing Date April 06, 2026

The letter was signed by Ahmad Tariq Hossanee, Director of Infinity Holdings. The confirmation provides clarity to investors regarding the unencumbered status of the promoter's shareholding in the pharmaceutical company for the specified period.

Historical Stock Returns for Jagsonpal Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
-0.20%-3.55%-4.17%-6.56%-13.18%+284.57%

Does Infinity Holdings plan to maintain this unencumbered status for the upcoming financial year?

How might this clean holding status influence Jagsonpal Pharmaceuticals' ability to secure future financing?

Could this signal a potential increase in promoter stake or a reduction in the same?

Jagsonpal Pharmaceuticals
View Company Insights
View All News
like18
dislike

Jagsonpal Pharmaceuticals extinguishes 16 lakh shares

2 min read     Updated on 03 Jun 2026, 02:39 AM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Jagsonpal Pharmaceuticals Limited extinguished 16,00,000 equity shares on June 02, 2026, pursuant to SEBI Buy-Back Regulations. The share capital reduced to ₹13,10,78,300, with promoter holding increasing to 69.36%.

powered bylight_fuzz_icon
41941736

*this image is generated using AI for illustrative purposes only.

Jagsonpal Pharmaceuticals Limited has extinguished 16,00,000 equity shares following the completion of its buyback offer on June 02, 2026. The extinguishment was carried out on a proportionate basis through the tender offer route pursuant to the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018. This corporate action reduces the total number of issued, subscribed, and fully paid-up equity shares from 6,71,39,150 to 6,55,39,150, bringing the post-buyback share capital to ₹13,10,78,300.

Share Capital Reconciliation

The reconciliation of the company's share capital pre and post-extinguishment confirms that all 16,00,000 shares bought back were in dematerialized form, with no shares tendered in physical form. The equity shares extinguished carry a face value of ₹2 each. The process was verified by the Registrar to the Buyback Offer, MCS Share Transfer Agent Limited, and certified by the company's Managing Director and Non-Executive Director in compliance with Regulation 11 of the Buyback Regulations.

Particulars No. of Equity Shares Amount (in ₹)
Pre-extinguishment: Issued, subscribed and fully paid-up share capital 6,71,39,150 13,42,78,300
Less: Equity Shares bought-back (Dematerialized Form) 16,00,000 32,00,000
Post extinguishment: Issued, subscribed and fully paid-up share capital 6,55,39,150 13,10,78,300

Depository Confirmations

National Securities Depository Limited (NSDL) executed the debit of 1,600,000 equity shares on May 27, 2026. Central Depository Services (India) Limited (CDSL) also confirmed the buyback, noting that the capital of the company recorded with CDSL post-buyback stands at ₹13,10,78,300. The extinguishment was finalized based on the public announcement dated April 28, 2026, and the letter of offer dated May 6, 2026.

Shareholding Pattern Post-Buyback

The extinguishment of shares has altered the shareholding pattern of the company. The Promoter and Promoter Group's holding has increased to 69.36% of the post-buyback equity share capital, while Foreign Investors now hold 30.64%. The total number of equity shares post-buyback stands at 6,55,39,150.

Category Pre-Buyback Shares % of Pre-Buyback Capital Post-Buyback Shares % of Post-Buyback Capital
Promoter / Promoter Group 4,54,58,210 67.71 4,54,58,210 69.36
Foreign Investors 22,37,115 3.33 2,00,80,940 30.64
Financial Institutions / Banks & Mutual Funds 4,30,091 0.64 - -
Others (Public, Public Bodies Corporate etc.) 1,90,13,734 28.32 - -
Total 6,71,39,150 100.00 6,55,39,150 100.00

Historical Stock Returns for Jagsonpal Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
-0.20%-3.55%-4.17%-6.56%-13.18%+284.57%

How will the significant increase in Foreign Investors' stake to 30.64% influence Jagsonpal's strategic direction and governance?

What impact will the reduced equity base have on the company's earnings per share (EPS) and future dividend payouts?

Will the company consider further capital allocation strategies, such as dividends or additional buybacks, given the promoter group's increased holding?

Jagsonpal Pharmaceuticals
View Company Insights
View All News
like17
dislike

More News on Jagsonpal Pharmaceuticals

1 Year Returns:-13.18%